Introduction Cerebral arteriovenous malformations (AVMs) are curable with endovascular embolization¹ and precipitating hydrophobic injectable liquid (PHIL) is newer liquid embolic agent used in endovascular embolization of cerebral arteriovenous malformation (AVM).²

Aim of Study The aim of the study was to retrospectively assess treatment results in patients with cranial dural arteriovenous fistulas – the rate of total occlusions immediately after embolization and at 6-month follow-up examination.

Methods This was a retrospective descriptive study taking place in Pauls Stradins Clinical university hospital from December 2018 until November 2022 including eleven patients with dural arteriovenous fistulas firstly diagnosed and treated by injection of PHIL only or with PHIL in combination with other embolization products (such as Onyx and detachable coils).

Results There were 10 patients (91%) treated with PHIL only and 1 patient treated with PHIL, coils and Onyx. In 10 patients (91%) there was total occlusion (TO) immediately after treatment achieved and in one patient there was partial occlusion (PO). There were no patients undergoing embolization repeatedly and there were no post-embolization adverse effects. In 7 patients (63%) there was a follow-up examination performed with DSA or MR/MRA, median time after embolization was 6 months and TO was seen in 6 patients, but 1 patient (14.3%) – the one with PO from the beginning.

Conclusion It is safe to use PHIL for endovascular treatment of cranial dural arteriovenous fistulas with very good TO rate and very little possibility of complications after the treatment.

References

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7963645/

2. https://neurointervention.org/upload/pdf/neuroint-2022-00199.pdf

Disclosure of Interest Nothing to disclose